Protease

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 29, 2024
Retina, Chair, Three Months, Biologics license application, Secretome, Disease, Infection, Incidence, Paratriathlon, Inflammation, Patient, Sale, Limbal stem cell, Research, CIRM, Acquisition, Commercial, Eye, Safety, Retinitis pigmentosa, Food, FDA, BLA, Stargardt disease, Physician, Contingency, Protease, Cryptocurrency

ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • “In 2023, we focused on clinical execution, advancing our Phase 2b CHASE trial of KPI-012 for the treatment of PCED.
  • In December 2023 and March 2024, KALA announced private placement financings with an institutional investor, priced at-the-market under Nasdaq rules.
  • Cash Position: As of December 31, 2023, KALA had cash and cash equivalents of $50.9 million, compared to $56.1 million as of September 30, 2023.
  • Operating Loss: For the quarter ended December 31, 2023, loss from operations was $9.6 million, compared to $10.3 million for the same period in 2022.

Orphan designation: (S)-2-isobutyrylamino-pentanedioic acid 5-amide 1-{[(2S,5S,8S,11R,12S,15S,18S,21R)-2,8-bis-((S)-sec-butyl)-21-hydroxy-5-(4-hydroxy-benzyl)-15-isobutyl-4,11-dimethyl-3,6,9,13,16,22-hexaoxo-10-oxa-1,4,7,14,17-pentaaza-bicyclo[16.3.1[...]

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Failure, Civil service commission, Enzyme, Protease, Disease, Infection, Inflammation, Patient, Committee, Knowledge, Netherton syndrome, Regulation, EMA, IRIS, Life, Protein, Kallikrein, European, Skin, COMP, Water, Safety, European Commission, MDC, Calcineurin, Moisturizer, Steroid, Syndrome, Medicine, Pharmaceutical industry

Orphan designation: (S)-2-isobutyrylamino-pentanedioic acid 5-amide 1-{[(2S,5S,8S,11R,12S,15S,18S,21R)-2,8-bis-((S)-sec-butyl)-21-hydroxy-5-(4-hydroxy-benzyl)-15-isobutyl-4,11-dimethyl-3,6,9,13,16,22-hexaoxo-10-oxa-1,4,7,14,17-pentaaza-bicyclo[16.3.1]docos-12-yl]-amide} Treatment of Netherton syndrome, 17/10/2019 Positive

Key Points: 


Orphan designation: (S)-2-isobutyrylamino-pentanedioic acid 5-amide 1-{[(2S,5S,8S,11R,12S,15S,18S,21R)-2,8-bis-((S)-sec-butyl)-21-hydroxy-5-(4-hydroxy-benzyl)-15-isobutyl-4,11-dimethyl-3,6,9,13,16,22-hexaoxo-10-oxa-1,4,7,14,17-pentaaza-bicyclo[16.3.1]docos-12-yl]-amide} Treatment of Netherton syndrome, 17/10/2019 Positive

Verseon Gains US Patent Protection for Compounds that Could Eliminate Bleeding Risks of Current Anticoagulants

Retrieved on: 
Wednesday, January 24, 2024
Risk, Stroke, Bleeding, Protease, Patent, Patient, Verseon, Splenic infarction, Anticoagulant, Cardiovascular disease, CSO, Pharmaceutical industry

FREMONT, Calif., Jan. 24, 2024 /PRNewswire/ -- Verseon is pleased to announce that the USPTO has issued a new patent, "Thrombin Inhibitors, Formulations, and Uses Thereof," that further extends intellectual property protection for Verseon's novel class of thrombin inhibitors. These anticoagulant compounds promise to open new and safer treatment options for many of the world's 400+ million cardiovascular disease patients.

Key Points: 
  • These anticoagulant compounds promise to open new and safer treatment options for many of the world's 400+ million cardiovascular disease patients.
  • Unlike current anticoagulants, Verseon's Precision Oral Anticoagulants (PROACs) covered by this patent exhibit a unique mechanism of action that does not increase the risk of bleeding yet prevents the formation of the dangerous blood clots behind heart attacks and strokes.
  • Because these compounds are also highly selective against other serine proteases, they are expected to cause fewer side effects.
  • "We are pleased by the USPTO's decision to grant additional patent protection for our PROACs," said Verseon's CSO David Kita.

Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 70, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Peripheral neuropathy, Diarrhea, Marketing, Zidovudine, European Commission, Protease, Pharyngitis, INN, Immune system, Heartburn, HIV/AIDS, Fatigue, Saquinavir, Darunavir, ATC, Depression, Itch, Ritonavir, AIDS, International, Capsule, Cough, European, Headache, Disease, CD4, Ageing, Body surface area, Blood, Sore throat, Nausea, Rash, Language, Mouth, Abdominal pain, Dizziness, Flushing, Infection, Food, Indigestion, HIV, Tablet, Chronic pain, Reproduction, Back pain, Select, Committee, Patient, Dysgeusia, Risk management, Anatomy, Medicine, Paresthesia, Vomiting, IIA, Lopinavir, CHMP, Viral load, Vaccine

Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 70, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 70, Status: Authorised

Human medicines European public assessment report (EPAR): Kaletra, lopinavir,ritonavir, Date of authorisation: 19/03/2001, Revision: 62, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Medical Subject Headings, Common, Diarrhea, Marketing, HIV-1, European Commission, Agency, Protease, HIV, INN, Immune system, Upper respiratory tract infection, ATC, Nelfinavir, Depression, EMA, AIDS, International, Capsule, European, Ageing, Nausea, Blood, Language, European Medicines Agency, Infection, Food, Ritonavir, Tablet, Reproduction, Select, Patient, Human, Liver disease, Anatomy, Medicine, IIA, Lopinavir, Viral load, Vaccine

Human medicines European public assessment report (EPAR): Kaletra, lopinavir,ritonavir, Date of authorisation: 19/03/2001, Revision: 62, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Kaletra, lopinavir,ritonavir, Date of authorisation: 19/03/2001, Revision: 62, Status: Authorised

Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

Retrieved on: 
Monday, November 13, 2023
World Health Organization, Viral, Protease, Research, Safety, Disease, MERS, Gastroenteritis, CFO, Influenza, COCP, Death, FDA, Vaccine, Merck, G&A, Pharmacokinetics, COVID-19, Therapy, CDC, RNA, R, SARS-CoV-2, Cocrystal, A, SARS, Enzyme, Pharmaceutical industry, Cryptocurrency, Medical device, Norovirus

Our drug discovery process differs from traditional, empirical medicinal chemistry approaches that often require iterative high-throughput compound screening and lengthy hit-to-lead processes.

Key Points: 
  • Our drug discovery process differs from traditional, empirical medicinal chemistry approaches that often require iterative high-throughput compound screening and lengthy hit-to-lead processes.
  • Research and development (R&D) expenses for the third quarter of 2023 were $4.2 million, compared with $3.9 million for the third quarter of 2022.
  • Cocrystal reported unrestricted cash as of September 30, 2023 of $29.7 million, compared with $37.1 million as of December 31, 2022.
  • The Company had working capital of $30.3 million and 10.2 million common shares outstanding as of September 30, 2023.

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Sale, Eye, Stargardt, Three Months, Protease, Acquisition, Research, Safety, Retinitis pigmentosa, Food, BLA, D, Commercial, Chair, CIRM, Stem cell, Patient, Secretome, FDA, CHASE, MSC, Infection, Stargardt disease, R, Nine Months, Paratriathlon, Biologics license application, Contingency, Pharmaceutical industry, Cryptocurrency, Vaccine, Clothing, Video game, Fine chemical, Life insurance, Security (finance), Drug, Alcon

ARLINGTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe diseases of the eye, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • Cash Position: As of September 30, 2023, KALA had cash and cash equivalents of $56.1 million, compared to $70.5 million as of December 31, 2022.
  • R&D Expenses: For the quarter ended September 30, 2023, research and development (R&D) expenses were $5.6 million, compared to $5.4 million for the same period in 2022.
  • Operating Loss: For the quarter ended September 30, 2023, loss from operations was $8.8 million, compared to $14.6 million for the same period in 2022.
  • The weighted average number of shares used to calculate net loss/income per share was 2.6 million for the quarter ended September 30, 2023 and 1.5 million for the quarter ended September 30, 2022.

Global HIV Diagnostics and Therapeutics Markets Report 2023-2028 with Competitive Analysis of Medtronic, Abbott, Sanofi, Roche, Bio-Rad Laboratories, and Danaher - ResearchAndMarkets.com

Retrieved on: 
Monday, November 13, 2023
Infectious Diseases, Pharmaceutical, AIDS, Health, Polymerase chain reaction, FDC, Protease, STR, Therapy, HIV/AIDS, ART, Stephen Porter (professor), Social stigma, Viral load, WHO, Medtronic, Risk, EIA, Sanofi, Patient, PCR, NAT, Danaher Corporation, ELISA, CD4, HIV, Diagnosis, Roche, Growth, Pi, Medical device, Pharmaceutical industry, Vaccine, Marketing

The "Diagnostics and Therapeutics for HIV: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diagnostics and Therapeutics for HIV: Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The global market for diagnostics and therapeutics for HIV was valued at $28.8 billion in 2022.
  • The global HIV therapeutics market is poised for significant growth, with a focus on various drug classes.
  • It covers current regulations and guidelines for HIV diagnostics and therapeutics, presenting a survey of leading market players.

Bioxytran Gets Broad Patent Coverage on 60+ Viruses

Retrieved on: 
Tuesday, October 24, 2023
RSV, Patent, Epstein–Barr virus, Viral, HAART, Reading, Lectin, Nipa, Hepatitis C, Measles, Protease, Pathology, HIV, Intellectual property, Virus, Cell, Research, Drug development, COVID-19, Mumps, MOA, Virology, Rubella, Simplex, Shingles, Drug resistance, Movement, Enzyme inhibitor, Plasma protein binding, DNA, Vaccine, Pharmaceutical industry, H1N1, Galectin

BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral diseases, announced that the U.S Patent and Trademark Office (USPTO) has published the Company’s patent application WO2023178228A1 Lectin-binding carbohydrates for treating viral infections. The pending patent covers broad claims about the use of hundreds of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses.

Key Points: 
  • The pending patent covers broad claims about the use of hundreds of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses.
  • This patent represents what we believe is a new direction in the evolution of antiviral therapies that originally started during the HIV epidemic.
  • This pending patent with its broad claims also shows the Company is well-positioned with respect to its intellectual property portfolio.
  • This patent covers some of the largest indications in virology and includes viruses like COVID-19, influenza, herpes, Epstein-Barr, shingles, hepatitis C, measles, mumps, and rubella.

Global Plasma Fractionation Market Valued at $5 Billion in 2023, Expected to Surge with 10% CAGR by 2035 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023
Health, Pharmaceutical, Government, Partnership, COVID-19, Pharmacy, Prevalence, CSL, Therapy, Primary immunodeficiency, Ageing, Protease, Rare, Takeda Pharmaceutical Company, Type, Antibody, Collection, Bio Products Laboratory, Growth, Takeda, BPL, Patient, Albumin, Blood product, Rare-earth element, Pharmaceutical industry, Sintering, Grifols, Plasma

The global plasma fractionation market is currently estimated to be worth $5 billion in 2023 and is poised to exhibit a compounded annual growth rate (CAGR) of approximately 10% during the forecast period from 2023 to 2035.

Key Points: 
  • The global plasma fractionation market is currently estimated to be worth $5 billion in 2023 and is poised to exhibit a compounded annual growth rate (CAGR) of approximately 10% during the forecast period from 2023 to 2035.
  • Plasma Collection Centers in the US: Currently, the United States is home to approximately 80% of the world's plasma donation centers.
  • The country supplies over 70% of the plasma used in the manufacturing of plasma-derived therapies through the process of plasma fractionation.
  • Importance of Plasma Fractionation: Plasma fractionation is a critical process for separating and purifying key blood plasma components, including immunoglobulins, albumins, anticoagulant factors, and protease inhibitors.